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Abstract: In early 2014, a relatively obscure virus, the Zika virus, made headlines worldwide
following an increase in the number of congenital malformations. Since then, research on Zika
virus, treatment and vaccines have progressed swiftly with various drugs being repurposed and
vaccines heading into clinical trials. Nonetheless, the need for a vaccine is crucial in order to eradicate
this re-emerging arthropod-borne virus which remained silent since its first discovery in 1947. In this
review, we focused on how the inconspicuous virus managed to spread, the key immunological
factors required for a vaccine and the various vaccine platforms that are currently being studied.
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1. History of Zika Virus
Zika virus (ZIKV) was first isolated within the Zika forest in Uganda back in 1947 when a group
of scientists working on yellow fever unexpectedly discovered an unknown new virus from a sentinel
rhesus macaque [1]. It was then characterized and classified as an arthropod-borne virus belonging
to the Flaviviridae family and Flavivirus genus. Years later, the first confirmed human ZIKV infection
case came in 1952 when live virus was isolated from a patient in Eastern Nigeria [2]. Since then, it was
confirmed that ZIKV is a human viral pathogen.
The first recorded human outbreak of ZIKV originated on the Island of Yap in 2007 whereby an
estimated 73% of the population were infected. Prior to this, there were only 14 reported human ZIKV
infections [3]. Subsequently, in 2008, Foy et al., found evidence that human-to-human transmission
of ZIKV was plausible through sexual intercourse [4]. Unfortunately, the start of 2012 ushered in
a wave of various mosquito-borne diseases which included Zika, Chikungunya and Dengue virus
in the Pacific islands [5,6]. A routine check of blood donations in French Polynesia found samples
which were positive for ZIKV when tested using PCR, triggering a closer surveillance of the spread of
ZIKV [7]. In November 2013, the first suspected case of perinatal transmission of ZIKV was reported
in the French Polynesia where a newborn had symptoms of mild pruritic rash at the time of delivery
with the mother displaying symptoms of ZIKV infection two weeks prior delivery [8].
Following the recent surge of ZIKV cases in 2013 and 2014, an increase in congenital cerebral
malformations, brainstem dysfunction and microcephaly among fetuses and newborns were observed,
however the cause was unknown [9]. It was only when the Brazilian Government reported a correlation
between ZIKV virus infections with congenital malformations in November 2015 that triggered health
authorities to keep a vigilant watch for this inconspicuous disease [10]. By February 2016, a public
health emergency was declared following proof of the association between ZIKV, microcephaly and
other neurologic disorders such as the Guillain-Barre syndrome.
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2. Treatment
Due to the massive outbreak of ZIKV infection in 2015 without a known cure, various groups
have been working on repurposing FDA-approved drugs for treatment [11–13]. Repurposing drugs
would save a lot of time spent on finding and testing new molecules as human pharmacological data
could be found in the pharmacopoeia; however more studies are needed to address issues such as the
concentration of drugs needed to kill 90% of the virus and the drug exposure levels in the relevant
organs or tissues. There are currently no FDA approved drugs under investigation in clinical trials
solely for the treatment of ZIKV infection [14]. Hence despite efforts to repurpose known drugs for
treatment, there is still an urgent need for a vaccine against ZIKV due to its implications for a pregnant
mother and child.
3. Challenges for a Zika Vaccine
There are many challenges when designing a vaccine targeting ZIKV. Firstly, there is currently
no perfect small animal model for pre-clinical testing. Wild-type (WT) mice are poorly susceptible to
Zika infection and develop low and short-lived viremia without apparent pathologies [15–18]. This is
due to the strong type I interferon response during the first days of infection [19,20]. Mice deficient
in molecules of this pathway have been shown to sustain high viremia and display a large array of
pathologies [16]. WT models includes the use of antibodies against the interferon alpha/beta receptor
have also been used extensively as a model [16]. Thus, so far, non-human primates (NHP) which is
one of the natural reservoirs of the virus are the best pre-clinical models as discussed in depth by
Lee & Ng [19]. The cost and maintenance of testing vaccines on NHP is extremely high and this poses
a hurdle in vaccine development. As ZIKV is linked to congenital malformations, one of the toughest
hurdles to overcome is the need for a vaccine which is safe for pregnant women and their offspring.
Another key challenge in designing a vaccine against ZIKV is the possible risk of antibody-dependent
enhancement of heterologous flavivirus infection such as dengue due to the sequence and antigenic
similarity between them. This has clearly been showcased in the clinical trials of a dengue vaccine
developed by Sanofi [21].
4. Structure of Zika Virus
A clear understanding of structure-based functional analyses of the virus is needed in order to
design a vaccine against ZIKV. ZIKV has a structure akin to other flaviviruses, an icosahedral symmetry
with a radius of 220 Å [22] (Figure 1). The full genome of ZIKV contains 11,000 bases which is enclosed
by a lipid membrane encoding three structural proteins i.e. capsid (C), pre-membrane (prM), envelope
(E) and seven non-structural (NS) proteins i.e. NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 [23,24].
The icosahedral shape of the virus is attributed to the C protein which comprises the viral capsid whilst
the outer transmembrane is decorated with E and prM/M proteins [22], which is the most commonly
used target in vaccine designs which is further discussed in this review. In a resting state, the immature
virus contains 60 trimeric E:M heterodimers, however, these particles lose their spiky surface following
maturation process and cleavage of prM [23]. Consequently, the fusion loop is exposed, allowing the
particles to fuse and become infectious in the low pH environment in the endosomes.
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Figure 1. Structure of ZIKV. 
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response leading to memory. 
Most of the vaccines against ZIKV today focus on the induction of long-lived neutralizing 
antibody (nAb) responses. This was based on the fact that prophylactic and curative treatments with 
monoclonal antibodies against Zika have been shown to protect mice or NHP against ZIKV 
challenges [26,27] Thus Zika vaccines should induce long-lasting memory B cells. B-cells internalize, 
and process viruses or vaccine molecules. These cells present viral antigen-derived peptides on their 
MHC II. After maximum activation and amplification, most B cells will die, and a fraction of B cells 
will be developed into B cell memory [25,28,29]. It has to be noted that a ZIKV vaccine will also need 
to induce good Zika-specific helper T cell responses, since activated T-helper recognizing MHC 
II/antigen complex found on B-cells promotes B cell multiplication, antibody maturation and 
secretion [25].  
6. Vaccine Formulations 
6.1. Live Attenuated Virus (LAV) Vaccine 
Live attenuated virus vaccine is arguably one of the favored vaccination strategies due to their 
previous success with the yellow fever virus vaccine, YF-17D, in the 1930s. A single dose of YF-17D 
vaccine is able to induce high titers of nAb which confers protection on at least 95% of recipients 
[30,31]. This strategy has been employed with many other diseases such as polio, measles and mumps 
[18]. Moreover, the production of attenuated vaccine is cost effective and fairly simple in comparison 
to other vaccine strategies. 
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5. Immunity Induced by ZIKV Vaccines
Vaccination is the most effective strategy for combating infectious diseases and has saved millions
of lives. A successful vaccine should be able to induce efficient immune responses and generate
immunological memory to provide long lasting protection against the particular pathogen [25]. In this
section, we discuss a brief overview of how anti-Zika vaccines should trigger an immune response
leading to memory.
Most of the vaccines against ZIKV today focus on the induction of long-lived neutralizing antibody
(nAb) responses. This was based on the fact that prophylactic and curative treatments with monoclonal
antibodies against Zika have been shown to protect mice or NHP against ZIKV challenges [26,27] Thus
Zika vaccines should induce long-lasting memory B cells. B-cells internalize, and process viruses or
vaccine molecules. These cells present viral antigen-derived peptides on their MHC II. After maximum
activation and amplification, most B cells will die, and a fraction of B cells will be developed into B cell
memory [25,28,29]. It has to be noted that a ZIKV vaccine will also need to induce good Zika-specific
helper T cell responses, since activated T-helper recognizing MHC II/antigen complex found on B-cells
promotes B cell multiplication, antibody maturation and secretion [25].
6. Vaccine Formulations
6.1. Live Attenuated Virus (LAV) Vaccine
Live attenuated virus vaccine is arguably one of the favored vaccination strategies due to their
previous success with the yellow fever virus vaccine, YF-17D, in the 1930s. A single dose of YF-17D
vaccine is able to induce high titers of nAb which confers protection on at least 95% of recipients [30,31].
This strategy has been employed with many other diseases such as polio, measles and mumps [18].
Moreover, the production of attenuated vaccine is cost effective and fairly simple in comparison to
other vaccine strategies.
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Kwek et al., isolated a small-plaque ZIKV variant by passaging French Polynesian ZIKV isolate in
Vero cells and in C6/36 cells prior to infection on BHK-21 cells [32]. These few passages resulted in a
small proportion of genetic variants, of which smaller plaques were selected. The authors picked the
smallest variant of ZIKV, encoded DN-2, which had a substitution of alanine to guanine at position 948.
This corresponded to a methionine to valine change in the amino acid sequence of the membrane gene.
Nonetheless, DN-2 was able to infect monocyte-derived APCs, human umbilical vein endothelial cells,
human embryonic stem cell-derived endothelial progenitor cells and HuH-7cells at significantly lower
levels in comparison to other ZIKV strains. Subsequently, A129 mice which were inoculated with
DN-2 were able to survive a 104 PFU challenge without any weight loss or detectable viremia in the
peripheral circulation. However, in a subsequent study, 40% of mice had low levels of DN-2 RNA in
the testes 15 days post-challenge. The authors also looked at attenuated maternal-fetal transmission
in A129 dams following inoculation and challenge. Fetuses of DN-2 infected dams did not show any
pathological differences from the uninfected dams however, one of the fetuses did succumb to infection.
Another issue concerning the use of LAV in this study is the stability of the virus. The authors noted
that DN-2 is stable up to 7 passages, which questions the stability of the LAV that may have resulted in
genetic variants in the following passages.
Shan et al., manipulated the complementary deoxyribonucleic acid (cDNA) clone of the ZIKV
Cambodian strain FSS13025 with various deletions to mutate the local RNA structure of the viral
3’UTR which was consequently transfected into Vero cells [33–35]. Immunogenicity and efficacy
were then tested on AG129 mice where the authors showed that the nAb titers of mice immunized
with mutated virus were comparable to those induced by the wildtype. In addition, mice inoculated
with the mutated virus showed a delay in the peak viremia which was a 100-fold lower than the
wild type (WT) [34]. Subsequently, the mice were challenged intraperitoneally with the Puerto Rican
strain (PRVABC59 ZIKV). Interestingly, the authors found that mice immunized with mutated virus,
produced four-fold higher levels of IFN-γ than those immunized with the wild type. Remarkably, none
of the A129 mice which received the mutated virus showed any detectable viremia in the periphery
circulation or organs following challenge. The results facilitated in narrowing down the groups of
mutated viruses for their potential vaccine candidate i.e. virus with 10 nucleotide deletions (del-10).
Subsequently, the authors evaluated the neurovirulence of del-10 through intracranial immunization
of CD-1 pups with lower virus challenging doses. A dose as low as 10 IFU of WT virus resulted in
25% mortality whereas all the pups given del-10 survived. Finally, the authors exposed Aedes aegypti
mosquitoes to artificial blood meals containing either WT virus or del-10. Following 7 days incubation,
56% of the engorged mosquitoes were infected with the WT virus but none with del-10 mutants [34].
In a follow up study, Shan et al. also tested the efficacy of del-10 to prevent vertical transmission in
C57BL/6 female mice, following anti-IFNAR treatment [35]. At day 28 post immunization, the authors
noted that all immunized mice developed high titers of nAb. Subsequently, the mice were mated and
monitored for vaginal plugs. Pregnant mice were challenged with mouse adapted ZIKV African strain
Dakar 41519 following anti-IFNAR antibody treatment. Mice vaccinated with a single dose of del-10,
had a significant reduction in viremia and in viral loads in tissues. As expected, the levels of nAb
titers were inversely correlated to the levels of infectious virus. The authors subsequently assessed
if del-10 was able to prevent testicular damage in male mice. Three weeks-old A129 male mice were
vaccinated with del-10 and subsequently challenged with PRVABC59. No viremia was detected in
mice immunized with del-10 unlike the sham vaccinated mice. In addition, there was no reduction in
total sperm or motile sperm counts in comparison to healthy uninfected mice. Results with vaccinated
male mice were in total contrast with the sham vaccinated mice, which saw a significant reduction
in both total and motile sperm counts. In addition, the pathology of the testes also differed whereby
mice vaccinated with del-10 did not show any reduction in size or weight unlike the sham treated
mice. Interestingly, these results were not reproducible in older male mice as the sham vaccinated
mice did not show any weight or size reduction. The others then tested their vaccine candidate on
non-human primates. Primarily, the authors evaluated the level of attenuation of their vaccine and
Vaccines 2018, 6, 77 5 of 18
found that only one of the four rhesus macaques showed detectable viremia. Subsequently, the authors
noted that the levels of nAb titers elicited in macaques vaccinated with del-10, were comparatively
lower than those inoculated with the WT ZIKV. However, both groups of macaques did not display
any viremia following challenge at day 56. This was in contrast to PBS vaccinated group where
high levels of viremia were detected. Neutralizing antibody titers increased between 10–100 folds in
mice vaccinated with del-10 however, no significant increase was seen in the group given WT ZIKV.
As del-10 was unable to confer sterilizing immunity in macaques, the authors tested another candidate,
annotated as del-20 (containing a 20 nucleotide deletion) as a second LAV candidate. The same sets of
experiments were performed to test the safety and immunogenicity of the vaccine candidate, del-20.
Male A129 mice were immunized with del-20 and by day 6, all mice had exhibited lower virus titers
in comparison to WT ZIKV inoculated mice. This was as expected as del-20 was previously shown
to be less attenuated than del-10 as it was less sensitive to type I interferon inhibition. Similar to
the results of del-10, when young (3-week-old) male A129 mice were challenged with PRVABC59
following immunization, the mice did not show any loss of sperm counts, zero detectable viremia
in testis or any changes in testis pathology. Interestingly, when neonate CD-1 mice were subjected
to 104 FFU of del-20 intracranially, there was a mortality rate of 29% whereas all neonates survived
when given 103 FFU of del-20. Aedes aegypti mosquitoes were then fed to a blood meal containing WT
ZIKV and del-20. 50% of mosquitoes fed with WT were infected with ZIKV whereas none showed
any viral RNA when fed with del-20. Finally, the authors proceeded with testing del-20 on macaques.
Two of the three macaques that were vaccinated with del-20 subcutaneously exhibited low levels
of viremia in various organs. Nonetheless, these NHPs soon developed high nAb titers by day 10
following vaccination. Subsequently, the three macaques were challenged with PRVABC59 on day 56
and displayed no viremia which the authors concluded that del-20 induces sterilizing immunity. In
conclusion, a live attenuated vaccine undoubtedly has its advantages of able to elicit strong immune
responses with a single dose, however, there are certain drawbacks to using live attenuated vaccines
as well. These include its limited use in immunocompromised or pregnant patients due to the risk
of adverse effects. Hence there is still a need for other avenues in order to provide complementary
options for controlling ZIKV infections.
6.2. Messenger RNA (mRNA) Vaccines
The use of mRNA vaccines is a relatively new trend that has gained popularity after it first made
headlines in the 1990’s. As the minimal genetic construct, mRNA is containing only the elements
required for expression of the specific encoded protein region. In addition, mRNA is incapable of
interacting with the genome but acts only as a transient carrier of information. Other advantages
for its use as vaccine platforms include its safety profile; as it is non-immunogenic, there is no risk
of potential infection unlike LAV [36]. 2017 saw an influx of new mRNA vaccines coming to play in
targeting the disease, however, one of the disadvantages of utilizing mRNA in an approach to vaccine
design is its rapid degradation by ribonucleases [37]. This setback however, could be easily tackled
with the use of delivery systems as discussed in the examples given below.
Early in 2017, Pardi et al. designed a mRNA vaccine against ZIKV utilizing the prM-E
glycoproteins of ZIKV H/PF/2013 with a modified nucleoside 1-methypseudourine which abrogate
innate sensing and increases mRNA translation in vivo [38]. mRNA was subsequently packaged
into lipid nanoparticles composed of ionizable cationic lipids, phosphatidylcholine, cholesterol and
polyethylene glycol. The authors initially tested the efficacy of their vaccine candidate on C57BL/6
mice which were given ZIKV-prM-E mRNA LNP intradermally. By week 8, vaccinated mice were
able to elicit high titers of IgG and nAb. Subsequently, similar studies were repeated in BALB/c
mice whereby mice showed peak antibody production by week 8. The authors proceeded with a
challenge study on the immunized BALB/c mice. Mice were challenged with PRVABC59 on either
week 2 or week 20 following immunization. Mice immunized with mRNA LNP did not exhibit
any detectable viremia in the blood whereas 8 out of 9 showed presence of viral RNA in the sham
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group. Consequently, the authors assessed the efficacy of their vaccine candidate on rhesus macaques.
Animals were immunized i.d. with varying doses of the vaccine. Interestingly, there were no significant
differences in E-protein specific IgG and nAb titers induced by the varying amounts of vaccine given
to the various groups of macaques. A challenge with the PRVABC59 virus was conducted 5 weeks
following immunization. Negative control animals which did not receive the vaccine were susceptible
to infection by day 3 post infection. In contrast, all vaccinated animals, regardless of the amount of
vaccine received, were protected against ZIKV infection with one exception. A macaque that received
the highest dose of vaccine had low transient viral RNA detected on day 3 however, it resolved by
day 5. Unsurprisingly, this macaque exhibited one of the lowest nAb titers amongst the group of
vaccinated animals. Further studies need to be conducted with bigger sample size as a single blip in
this study, had implications in determining correlates of protection.
In 2017, Richner et al., engineered a lipid nanoparticle encapsulating modified mRNA encoding
ZIKV prM/M and E genes from the Asian strain together with the signal sequence of human IgE
(IgEsig-prM-E LNP) [39]. The vaccine candidate, IgEsig-prM-E LNP, was initially assessed for its efficacy
in AG129 mice. Mice were injected intramuscularly (i.m.) with either a single or double dose of the
vaccine. The groups receiving two doses were able to elicit high titers of sera nAb. Subsequently, these
mice were challenged with ZIKV P6-740 (Malaysian strain) on day 42. Unsurprisingly, mice which
received two doses of the vaccine all survived with the exception of a single animal. Subsequently,
the authors tested the vaccine on immunocompetent C57BL/6 mice. Eight week old male mice were
given two doses of the vaccine prior to receiving anti-ifnar1 antibody and challenged. All mice
survived without detection of viremia post infection. As the fusion loop (FL) in DII of the E protein is
immunodominant in humans, there is a possible risk that vaccination with ZIKV full protein could
elicit cross-reactive antibodies which may enhance other flavivirus infection through ADE. Hence,
the authors generated mutations in the mRNA vaccine (IgEsig-prM-E FL LNP) and a series of Japanese
encephalitis virus (JEV) leader sequence replacing the IgE in mRNA LNPs i.e. JEVsig-prM-E-FL LNP,
to eliminate the antibody reactivity of FL-specific antibody. BALB/c mice vaccinated with JEVsig-prM-E
LNP showed the highest level of protection (one mouse had viral RNA detected in the brain) following
challenge with ZIKV Dakar 41,519 after anti-Ifnar1 treatment. Unfortunately, vaccine candidates
with FL mutations were unable to confer full protection as viral RNA was detected in some animals
albeit at much lower levels in comparison to the placebo LNPs. Similar to other studies, the authors
found that levels of nAb were inversely correlated to the levels of ZIKV RNA in the sera and tissues.
In order to evaluate whether the mutated vaccines were able to induce cross-reactive antibodies, sera
of vaccinated mice were incubated with dengue virus serotype 1 (DENV-1) RVP prior overlaying on
Fcγ receptor IIA-expressing K562 cells. As expected, sera from mice immunized with the FL mutation
displayed a lower peak sera enhancement titer (PET) i.e., a reduction in cross-reactivity. Subsequently,
authors passively transferred sera from vaccinated mice to AG129 mice 1 day prior to challenge with
DENV-2. Unsurprisingly, at least 80% of mice that had sera from the FL mutations survived with lower
morbidity clinical scores in comparison to those mice given the sera from full IgEsig-prM-E LNP.
6.3. DNA Vaccines
DNA vaccines are of the earliest vaccine platforms to be proposed for human clinical trials
following the ZIKV outbreak (clinicaltrials.gov). The use of genetically engineered DNA plasmids
encoding various antigens to induce both humoral and cellular responses has been explored against
various infectious diseases caused by parasites [40,41], bacteria [17,42] and other viruses [43,44]. Here,
we explore the recent advances of DNA vaccines against ZIKV infection focusing on those that have
reached studies on NHPs and human clinical trials.
Larocca et al. designed their DNA vaccine based on the pre-membrane and envelope (prM-Env)
of the Brazil strain BeH815744, scrapping the first 93 amino acids of prM [45]. The authors also tested
a few other vaccine candidates, carrying various mutations in the plasmid DNA prM-Env i.e. lacking
prM and/or lacking the transmembrane region or the full stem of Env, in parallel with their initial
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candidate. The immunogenicity of the various DNA plasmids was assessed using BALB/c mice. Mice
given prM-Env vaccine intravascularly was able to elicit higher Env-specific IgG titers in comparison
to all other groups. In addition, the prM-Env vaccine was also able to induce ZIKV-specific nAb and
Env-specific CD8+ and CD4+ T lymphocyte responses. Subsequently, a challenge study was performed
to determine the protective efficacy of DNA vaccine against a challenge using ZIKV PRVABC59 in
addition to Brazil/ZKV2015. Mice that were vaccinated with the complete prM-Env were completely
protected following challenge from the two different strains of ZIKV whereas the mice vaccinated with
mutated/truncated versions of the DNA vaccine, did not show complete protection against ZIKV-BR.
Furthermore, the authors tested the protective efficacy of the DNA vaccine on SJL and C57BL/6
mice which resulted in the same outcome whereby all mice given prM-Env DNA vaccine were fully
protected. Subsequently, Larocca and colleagues passively transferred purified IgG sera from BALB/c
vaccinated with prM-Env mice to naïve mice. Mice receiving sera Env-specific antibody titers of
above log 2.35, were protected against ZIKV-BR challenge. Next, prM-Env vaccinated mice were
depleted of CD8+ and CD4+ T lymphocytes prior challenge. Interestingly, depletion of T lymphocytes
did not abrogate the protective efficacy of the prM-Env DNA vaccine upon challenge. There was no
detectable viremia following challenge with ZIKV-BR however; viral RNA could be detected in the
unvaccinated group.
Abbink et al., extended this study by testing the protective efficacy of prM-Env DNA vaccine in
rhesus macaques [46]. Monkeys received two doses of the DNA vaccines intramuscularly four weeks
apart. Surprisingly, minimal nAb titers were only present on week 4 following primary immunization,
however titers increased following the boost. Despite low levels of nAb detected in the animals, the
monkeys had a 100% protection following a subcutaneous challenge with 103 PFU ZIKV-BR.
Muthumani et al. reported on a similar vaccine construct targeting the pre-membrane and
envelope proteins (prM-E) of ZIKV [47]. However, they added an IgE leader sequence to facilitate
better expression similar to the concept used by Richner et al. [39] for their mRNA vaccine. The authors
first tested the ability of the DNA vaccine to induce antigen specific T cells following intramuscular
vaccination. Splenocytes were harvested and tested for their ability to secrete IFN-γ following
ex vivo exposure to various peptide pools. Further evaluation of vaccine immunogenicity found
that the vaccination increased the proportion of vaccine-specific T cells which expresses TNF-α and
IFN-γ. Subsequently, the authors tested their vaccine efficacy by administering C57BL/6 mice with
DNA vaccine intramuscularly in a prime boost regimen. ZIKV-E-specific IgG antibody titers were
highest following a boosting, moreover titers were maintained even past day 60 post immunization.
Subsequently, the vaccine efficacy was tested on IFNAR-deficient mice. Similarly, sera from vaccinated
animals had detectable anti-ZIKV IgG by day 14 and also able to neutralize ZIKV though at relatively
lower levels in comparison to C57BL/6 mice. Mice were subsequently challenged with PR209 (Puerto
Rico) Zika virus following 2 doses of immunization. By the end of 3 weeks post challenge, all mice
that were received the vaccine survived compared to mice control mice which had a 30% survival
rate. Furthermore, the vaccinated animals did not show signs of morbidity unlike mice in the control
where all animals were presented with either weight loss or struggling with mobility. Subsequently,
the authors reduced the dose regimen by subjecting IFNAR-deficient mice to a single immunization
prior challenge. Even though mice vaccinated with the DNA vaccine survived, viral RNA could be
found in 40% of the mice. Muthumani et al. then tested their vaccine on NHPs. Macaques were
immunized using intradermal electroporation with the DNA vaccine twice, two weeks apart. Sera
and peripheral blood mononuclear cells (PBMCs) were collected on week 6 following immunization.
PBMCs stimulated with prM-E peptide pools showed that ZIKV prM-E immunization was able to
induce robust anti-ZIKV T cell responses in vaccinated RM. In addition, all vaccinated animals also
had significant increase in nAb titers. The immune sera of macaques were able to prevent ZIKV
infection in Vero, neuroblastoma and neural progenitor cells in vitro when tested via IFA. Sera from
vaccinated Rhesus macaques were adoptively transferred into IFNAR-deficient mice a day prior to
challenge. Mice which received control sera or PBS were all dead by day 8, however 80% of the mice
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receiving sera from vaccinated macaques survived. The study was further carried by a clinical trial
(NCT02809443) [48], whereby the vaccine was administered intradermally in a prime-boost regimen
consisting of 3 doses of vaccine. None of the patients reported any systemic adverse effect following
vaccination. At 14 weeks post vaccination, all participants had measurable ZIKV E protein specific
antibody titers; however, not all of the vaccinated individuals had nAb. Nonetheless, sera from the
participants were passively transferred to IFNAR-deficient mice prior to challenge with a lethal dose
of clinical strain ZIKV PR209 (Puerto Rico). Mice that received baseline sera or PBS, died within 9 days
of infection. Whereas 92% of the mice receiving sera from vaccinated individuals survived past day
14. Interestingly, mice which survived included those which received sera from individuals with no
detectable nAb. This provides further question for the use of nAb, determined in vitro, as a correlate
of protection.
Another DNA vaccine study conducted by Dowd et al. utilized the prM-E sequences inserted into
the cytomegalovirus immediate promoter cloned into plasmid VRC8400 [49]. However, the difference
between the constructs as published by Larocca et al. [45] and Abbink et al. [46], Dowd et al. included
the whole prM sequence which was based on the French Polynesian isolate H/PF/2013 virus and also
replaced the signal sequence of ZIKV prM with analogous region of JEV annotated as VRC5283. Based
on VRC5283, Dowd et al. designed a second vaccine construct which replaced the final 98 amino acids
of the stem and transmembrane regions of E protein with corresponding JEV sequence (VRC5288).
Both vaccines were able to induce of ZIKV-specific nAb production following a single immunization.
Subsequently, the authors optimized the dosage and regimen of their vaccine candidates. Macaques
were administered either two doses of 1 mg VRC5283 or 4 mg of either VRC5283 or VRC5288. Another
group of monkeys received a single 1 mg dose of VRC5288 and control animals were immunized with
the empty vector. Animals which were vaccinated with either VRC5283 or VRC5288 had significantly
higher nAb titers compared to the control. Moreover, macaques that received two doses of either
VRC5283 or VRC5288 had nAb titers which were significantly higher than those that received a single
dose. All animals were challenged 8 weeks following the first dose of vaccination with PRVABC59
ZIKV. Only animals which received double doses of vaccine were protected with the exception of one
animal which had blips on day 3 and 7. All other animals i.e. those receiving just one vaccination and
the control group, showed viremia by day 3. The vaccine constructs VRC5283 and VRC5288 advanced
to phase 1 clinical trials (NCT02840487 and NCT02996461) [50]. None of the healthy volunteers whom
were given either a two dose or three dose regimen reported any adverse side effects. Volunteers
were either given the vaccine intramuscularly using a needle syringe or a needle free device (Stratis
device, Pharmajet). Sera nAb titers could be detected 4 weeks following immunization. However,
the only group where all volunteers showed detectable levels of nAb were those given three doses of
VRC5283 using the needle-free device. This would have matched the NHP challenge model where the
macaques which were administered with VRC5283 showed better protection compared to VRC5288.
However, the authors did not utilize the needle free device when administering VRC5288 to any of the
patient groups, which makes it difficult to compare the vaccine efficacy of the two different candidates
in humans.
6.4. Adenovirus Vector Based
Adenovirus vectors have been well studied as a vector for gene and cancer therapy and also
vaccines whereby the vector expresses an unknown antigenic protein. Apart from its extensive safety
profile, the advantages of utilizing adenovirus vectors are that it is relatively stable, easy to attain high
titers and able to infect multiple cell lines which attributes to its potency.
Xu et al. manipulated a recombinant chimpanzee adenovirus type 7 (AdC7) by cloning the
gene encoding the signal peptide of JEV and full length ZIKV/M/E glycoproteins (AdC7-M/E) [51].
Vaccine immunogenicity was assessed in two groups of BALB/c mice immunized intramuscularly
with either a high or low dose adenovirus particles of recombinant AdC7-M/E. A booster dose was
performed 4 weeks following primary immunization. As E-specific antibody titers and nAb titers
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following primary immunization with high dose of virus particles were considerably high titer. There
were no significant difference titers following a booster dose. Subsequently, sera from vaccinated
BALB/c mice were tested for its ability to cross neutralize heterologous ZIKV strains, MR766, FSS13025
(Cambodia strain) and SMGC (Asian strain). The authors then tested the efficacy of the vaccine in
mice lacking type 1 interferon. IFNAR-deficient mice were given a single dose of AdC7-M/E and
antibody titers measured were of similar values as the BALB/c mice. Protection efficacy of the vaccine
was evaluated by challenging intraperitoneally with ZIKV-SMGC IFNAR-deficient mice that have
been immunized with one dose of vaccines. All sham mice succumbed to infection and died by
day 8, however all vaccinated mice (low and high dose) survived with no weight loss. The authors
then re-challenged the surviving vaccinated mice with a lethal dose of ZIKV. Astonishingly, there
were no viral RNA detected in either the blood or organs (brain, spleen, spinal cord, testes, liver) of
immunized mice. In contrast, sham immunized mice showed high levels of viral RNA in the blood and
tissues, especially the testes whereby there was fibrosis of the tissues and presence of inflammatory
cells. A passive immunization study was conducted to evaluate the protective efficacy of the vaccine.
Sera from BALB/c immunized mice were passively transferred intraperitoneally to immunodeficient
mice and subsequently challenged later with a lethal dose of ZIKV. All mice receiving sera from
vaccinated animals survived, however a slight decrease in weight could be seen between days 5 and 8
post immunization but quickly rebounded and increase steadily after day 8. Sham-immunized mice
succumbed to infection and died within 10 days.
In an independent study conducted by Guo et al. the authors manipulated a more commonly
used adenovirus, human type 5, expressing the pre-membrane and envelope proteins of ZIKV
strain MRS_OPY_Martinique_PaRi_2015 [52]. Three different constructs were designed, with
codon optimization to enhance transgene expression; Ad5-Luciferase (control), Ad5-Env and
Ad5-Sig-prM-Env. The authors first evaluated the vaccine efficacy by giving mice a single dose
of either vaccine or control (Ad5-Luc) intramuscularly. Vaccination with both vaccine constructs
were able to induce anti ZIKV-Env-specific antibodies which were significantly higher than Ad5-Luc.
Similarly, when the authors phenotyped T cells by flow cytometry and performed ELISPOT assay to
evaluate the cellular immune responses elicited by the vaccines, the levels of IFN-γ-, TNF-α-, IL-2-,
and CD107a-positive CD8+ T cells and IFN-γ- and TNF-α-positive CD4+ T cells in the vaccinated mice
were significantly higher than the control group. Nonetheless, for both immune responses, there were
no significant differences in antibody production or cytokine stimulation between the two vaccinated
groups. Unlike most studies whereby authors use immunodeficient mice, Guo et al. subjected mice to
corticosteroid (dexamethasone) therapy to mimic the scenario of patients with immunosuppression.
The two vaccines were able to elicit similarly high levels of anti-ZIKV-Env-specific binding antibodies
in sera at 2 weeks post vaccination even under glucocorticoid treatment. Interestingly, mice given
Ad5-Sig-prM-Env had significantly higher titers of anti-ZIKV specific nAb which also explain the
difference of viral RNA levels between the two vaccinated groups i.e. no detectable viral RNA in
sera and tissues of Ad5-Sig-prM-Env vaccinated mice and low levels in the Ad5-Env vaccinated mice
following challenge with PRVABC59. A similar result was seen when A129 mice were vaccinated
and challenged. Interestingly though, both vaccinated groups including the negative control, showed
weight loss, however, only mice vaccinated with Ad5-Sig-prM-Env had no detectable viremia in sera
or tissues. In addition, all mice vaccinated with Ad5-Sig-prM-Env survived lethal challenge whereas
only 83% of those vaccinated with Ad5-Env survived which could once again be due to higher levels of
sera anti-ZIKV specific nAb in Ad5-Sig-prM-Env vaccinated mice. The authors subsequently passively
transferred sera of vaccinated mice into naïve A129 mice prior to lethal challenge. Mice receiving sera
from Ad5-Sig-prM-Env vaccinated mice had a 100% survival rate with minimal weight loss and zero
detectable viral RNA in blood or tissues 6 days post infection. In contrast, mice receiving Ad5-Env only
had 66% survival rate, with detectable viral RNA in blood and tissues and weight loss. Nonetheless,
levels of detectable viral RNA were still significantly lower than those given sera of sham mice. This
study was the only study that tried to mimic vaccination efficacy in immunosuppressed patients which
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is critical prior to testing the vaccine in phase 2 clinical trials. There were differences in protective
efficacy of the two vaccine constructs, adenoviruses expressing prM-EnV and the -Env region, which
suggests that the prM region is fairly important which may be resulted from the particulate form
antigen (prM-EnV) and the non-particulate antigen (-Env). However, though there were no detectable
viremia or viral RNA in the tissues, the mice did suffer weight loss following challenge, which suggests
that the animals did succumb to infection but were able to recover.
6.5. Subunit Vaccines
Subunit vaccines comprise of a fragment of a pathogen, i.e. protein, or peptides. Unlike live
attenuated vaccines, subunit vaccines are generally a safer choice, however they tend to be less
immunogenic as well. Hence an adjuvant and/or multiple doses are required.
To et al. utilized a recombinant protein derived from the envelope protein of ZIKV (ZIKV E) based
on the French-Polynesian strain [53]. Immunogenicity was tested in various mouse models including
Swiss Webster (Swiss), BALB/c and also C57BL/6J mice. The authors initially tested their vaccine
candidate, a ZIKV E-based recombinant protein, either alone or formulated with various adjuvants
including alum-based adjuvants (Alhydrogel or Imject) or CoVaccine HT in Swiss mice. Mice that
were immunized with CoVaccine HT elicited the highest ZIKV E IgG antibody which was significantly
higher than those immunized with the ZIKV E together with alum adjuvants. Subsequently, when the
authors tested their various vaccine candidates in BALB/c and C57BL/6 mice, both formulations i.e.
alum and CoVaccine HT, of ZIKV E protein were able to induce high antibody titers with them showing
no significant difference between the two formulations. Neutralizing antibodies were measured using a
plaque reduction neutralization (PRNT) test following two doses of immunization of which the authors
found comparable titers of nAb in both groups. Subsequently, protection studies were performed
using BALB/c mice. Mice were intravenously challenged with PRVABC59 virus, four weeks post
immunization. Groups that were given two doses of vaccines were fully protected unlike those given
a single dose. Subsequently, authors tested if antisera from immunized mice would confer passive
protection against ZIKV challenge. 10 µg of pooled sera, together with the various adjuvants, was
administered intraperitoneally into BALB/c mice a day prior to challenge with ZIKV. The authors
concluded there was a decrease in ZIKV E specific IgG antibody titers 14 days post infection in
the group of mice receiving the antisera. Seroconversion was used as a gauge of virus infection in
unprotected mice, therefore the authors looked at antibody production against ZIKV NS1. All animals
presented with antibodies against ZIKV NS1 which suggested that mice receiving sera antibodies
were unprotected.
Another subunit vaccine derived from the ZIKV E protein of strain PRVABC59, was studied by
Yang et al. [54]. Unlike the previous study, Yang et al. utilized a specific portion of the E protein i.e.
the Domain III (DIII). ZIKV E DIII was produced in E. coli expression systems and subcutaneously
administered into C57BL/6 mice together with adjuvant (alum or TitreMax, a water in oil adjuvant).
Mice were given different doses of DIII. There was no significant difference in sera antibody titers
between groups of mice given different doses of antigen following the third immunization. The groups
of mice immunized with adjuvants were able to induce high titers of both IgG1 and IgG2c antibodies
with a bias towards IgG1 suggesting a Th-2 type response. Splenocytes from mice immunized with the
vaccine candidates were able to induce IFN-γ, IL-6 and IL-4 production in contrast to PBS immunized
mice, when stimulated with either EDIII or non-specifically with Con A. For both vaccine candidates,
more than 80% of the virus was neutralized in vitro. Subsequently, the authors tested the possibility
of antibody dependent enhancement activity of IgGs by incubating sera of immunized mice with
DENV-2 E domain protein. The mixture was subsequently incubated with K562 cells displaying the
human FcγR. The authors concluded that the purified IgGs from sera of mice immunized with ZIKV
D III vaccine did not display any ADE activity which is comparable to the negative control. However
further studies in in vivo models are needed to prove the vaccine is able to confer protection.
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Tai et al. conducted a long-term vaccination study using various fragments of recombinant
ZIKV EDIII (ZikaSPH2015 strain) which were codon optimized as vaccine candidates [55]. To test the
efficacy of their vaccine candidates, BALB/c mice were given four doses of the recombinant protein
together with alum or monophosphoryl lipid A (MPLA). Sera from immunized mice were collected
and IgG antibody titers were determined. All of the vaccine constructs tested were able to induce
nAb following immunization. However, nAb titers following immunization of recombinant protein
E298-409 were significantly higher than the other two; E296-406 and E301-404. Subsequently, long
term antibody titers were evaluated. Sera obtained at 10 months post immunization showed that all
vaccine constructs were able to elicit long term EDIII however, constructs E298-409 and E301-404 were
able to significantly induce higher E-specific IgG titers in comparison to E296-406. The authors then
tested if sera from immunized mice were able to protect pups against ZIKV infection. Pups born to
BALB/c mice 7 months post immunization, were challenged with two human epidemic strains FLR
(Colombia) and R103451 (Honduras). All pups which were born to mice immunized with ZIKV EDIII
fragments survived except for those which were born to those immunized with E301-404 which only
saw 83% survival when challenged with the Honduras strain. In contrast, pups from PBS immunized
mice died. Next, the authors conducted an adoptive transfer study using sera from mice immunized
with E298-409, which gave the highest titers of nAb. Seven-day old BALB/c pups were given immune
sera and challenged with ZIKV FLR and R103451. Unfortunately, only 80% of pups survived in both
challenged groups. Consequently, the authors tested the protective efficacy of sera obtained from
adult immunized mice transferred to A129 mice. Anti-E298-409 sera equal to 105 ZIKV EDIII-specific
IgG titer was transferred to A129 mice. A 100% survival was seen when the challenged with both
ZIKV strains. However, viral RNA was present in the brain, lung, liver, spleen and kidney 5 days
post infection in addition to tissue damage. The overall study identified that E298-409 as a promising
vaccine candidate which is able to stimulate high titers of maternal nAb and confer protection to
newborns. However, it is not known if maternal Ab are able to confer protection to the fetus if the
pregnant female mice were subsequently challenged with ZIKV. This would have been an important
study as we know that ZIKV is able to cross the placenta and cause fetal abnormality.
6.6. Combinatorial Vaccines
While the development of single ZIKV vaccine is ongoing, a multiple antigenic approach following
the measles mumps, rubella and varicella (MMRV) vaccine was being explored by Chattopadhyay and
colleagues [56]. In their combinatorial vaccine against Chikungunya virus (CHIKV) and ZIKV, they
utilized recombinant vesicular stomatitis virus (VSV) expressing CHIKV envelope polyprotein and
ZIKV E protein. Sera from BALB/C mice immunized with a single dose of 107 PFU of recombinant
VSV vaccine were able to neutralize 70% of ZIKV (Brazilian strain PE243). Whereas those which were
given two doses of the vaccine were able to neutralize 80% of ZIKV. In addition, sera from the single
immunization of BALB/C were also able to neutralize 100% of VSV∆G-eGFP/CHIKV pseudotype.
In order to determine the protective efficacy of the vaccine, 7 week old A129 mice were immunized
with 1 intramuscularly prior to challenge with either MR 766 Zika virus or CHIKV. Interestingly, none
of the vaccinated mice showed signs of viremia following infection with either viruses. Although
the authors proved that the mice were free from infection, the mice were past 15 weeks old when
challenged. In this particular murine model, it is known that ZIKV infection would not have resulted
in death of mice, but they would only show transient signs of illness following infection. Nonetheless,
the negative control mice given CHIKV succumbed to infection by day 3 whereas all immunized
mice survived. Overall, the study managed to prove that the vaccine was able to prevent viremia in
immunocompromised mice, though the authors did not mention of any physical signs of infection.
However, there was no proof that the vaccine would be useful in inducing production of maternal nAb
in pregnant dams which is able to confer protection to newborns. In addition, it would be interesting to
also study the possible deviations on the vaccine effects following co-infection with CHIKV and ZIKV.
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7. The Pros and Cons of Various Vaccine Platforms
The most common vaccine platform used today is the live attenuated vaccine. This includes the
chickenpox, rotavirus and the MMRV vaccines. The advantage of utilizing live attenuated vaccines
includes its strong humoral and cellular mediated response triggered. Hence, typically a single dose
of vaccine is needed. This proves useful in developing countries where the traveling time and cost
of returning to the clinic may be a problem. Nonetheless, the platform is not without its major flaw
where the organism may revert and cause more harm or immunosuppression [57]. This is a crucial
point to consider in the context of a ZIKV vaccine as the more susceptible group to vaccinate would be
the expectant mothers who already have a weakened immune system. Furthermore, it is known that
ZIKV persists for months in the semen and urine [58], which undoubtedly pose a huge risk of LAV
shedding into the semen.
Unlike live attenuated vaccines, nucleic acid vaccines are non-immunogenic on their own yet they
are also able to induce strong humoral and cellular mediated responses [59]. The major drawback of
ribonucleic acid vaccines is its ability to avoid degradation by circulating ribonucleases. In order to
deliver such vaccines, a delivery system is required. One major cause of concern is the possibility of an
insertion of foreign genomic sequences into the host genome which may alter the resulting immune
responses [60]. Even so, this is one of the more common vaccine platforms being used in the search for
a ZIKV vaccine due to its safety profile.
Recombinant subunit vaccines include those manipulating the viral/bacterial vector in order to
express the protein(s) of interest. The advantage of utilizing recombinant vaccine lies in its safety profile
and low production cost. However, due to its weak immunogenicity, there is a need for these vaccines
to be delivered with a potent adjuvant to boost the immune responses triggered by the antigen [61].
Conversely, with recent advances, we now have live recombinant vectors e.g. adenoviral vectors,
which assist in improving the immunogenicity of the vaccine. The recombinant adenoviral vectors
are widely used today thanks to its high transduction efficiency and transgene expression. However,
as most of the population have been exposed to adenovirus, there is a likelihood for pre-existing
immunity against the vector. This has been proven detrimental in a human immunodeficiency virus
(HIV-1) phase IIb vaccine trial whereby the vector-based vaccines provided favorable conditions for
HIV-1 replication [62]. The risk of utilizing such recombinant viral vector vaccine may not be of
concern for immunocompetent individuals, however, as the vaccine is more important to expectant
mothers, the risk may outweigh the benefit.
Unfortunately, we are unable to provide a detailed summary of every vaccine study that has been
published, however, relevant references are provided in Table 1. Nonetheless, each individual vaccine
platform has its own pros and cons which may not be suitable for the entire population. However, as
the essential targets for the vaccine are pregnant mothers, the need to ensure the safety profile is crucial
to not harm the mother and fetus in addition to the vaccine being able to induce nAb production and
prevent vertical transmission.
Table 1. Types of vaccines and phases of research.
Vaccine Type of Vaccine Sponsor Phase
ZIKA-001 * DNA plasmid vaccine GeneOne Life Science Phase 1
GLS-5700 * [48] DNA plasmid vaccine GeneOne Life Science Phase 1
mRNA-1325* mRNA vaccine Moderna Therapeutics Phase 1/2
MV-ZIKA * Recombinantmeasles-Zika vaccine Themis Bioscience Phase 1





ZPIV * ZIKV purifiedinactivated vaccine NIAID Phase 1
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Table 1. Cont.





Valneva Austria GmbH Phase 1
VRC-ZKADNA085-00-VP * [50] DNA vaccine NIAID Phase 1
rZIKV/D4∆30-713 * Live attenuated ZIKVvaccine NIAID Phase 1





Pre-clinical mouse model NHP
Live attenuated Zika vaccine Whole virus[32–35,65–67] Pre-clinical mouse model NHP
Live ZIKV chimeric vaccine (YF 17-D attenuated backbone) Whole virus [68,69] Pre-clinical mouse model
Adenoviral vector type 26 Whole virus [70] Pre-clinical mouse model NHP
Recombinant protein
E protein [54,55,71–73]
Capsid (C) PrME +
NS2B/NS3 proteins [74]
Pre-clinical mouse model
Adenoviral vector type 2 PrME protein + NS1protein [75] Pre-clinical mouse model
Recombinant VSV
Membrane (M) E [56]
PrME [76]
PrME + NS1 [77]
Pre-clinical mouse model
Chimpanzee adenoviral vector PrME protein [78] Pre-clinical mouse model
Outer membrane vesicles from Neisseria Meningitidis
(Proteosome) Whole virus [79] Pre-clinical mouse model
“Sementis Copenhagen Vector” (SCV) system PrME protein [80] Pre-clinical mouse model
Human adenoviral vector type 5 PrME protein [52] Pre-clinical mouse model
Recombinant chimeric ZIKV vaccine candidate
(JEV backbone) PrME protein [81] Pre-clinical mouse model
Recombinant chimpanzee adenovirus type 7 PrME protein [51] Pre-clinical mouse model
Modified Vaccinia Ankara (MVA) vector NS1 protein [82] Pre-clinical mouse model
Plant produced ZIKV E protein E protein [83] Pre-clinical mouse model
Virus like particles PrME protein [84] Pre-clinical mouse model
RNA nanoparticle vaccine PrME protein [85] Pre-clinical mouse model
Insect cell-produced subunit vaccine E protein [53,86] Pre-clinical mouse model
* Adapted from clinicaltrials.gov as of 18 October 2018.
8. Conclusions
The quest for a vaccine against ZIKV has progressed tremendously since the outbreak of 2014.
However, one of the biggest conundrums in vaccine research is finding a vaccine that is applicable
to the vast majority. Until today, most of the vaccine study focuses on the protective efficacy without
considering the need to vaccinate immunosuppressed patients as well. As Zika research progresses,
it is evident that the two different lineages found throughout the world have various infectivity and
potency which needs to be considered when performing challenge experiments. The current trends
of vaccines against ZIKV mainly concern the pre-membrane, membrane and envelope proteins as
the target epitopes for vaccine candidates due to the natural structure of the virus. It is essential to
note that most of these studies focus on a single vaccine candidate, with the more comprehensive
approach performed by Abbink et al. which compared three different vaccine approaches i.e. purified
inactivated vaccine, DNA vaccine and adenovirus vector vaccine [44] in a single study. Although
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many dwell on neutralizing antibodies as a predictor for protective efficacy, correlates of protection
remain to be defined. As a number of vaccines are already being tested or completed the first phase in
clinical trials, it is likely that a vaccine will be available in the coming future.
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